The investigational long-acting, once-weekly prodrug lonapegsomatropin (TransCon hGH) may be more beneficial to treatment-naïve pediatric patients with growth hormone deficiency (GHD) than daily somatropin of equivalent weekly dose, according to a paper recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Aimee D. Shu, MD, of Ascendis Pharma (who funded the...
From ENDO2021: Phase 3 Trial Results Show Patient Preference for First Oral Therapy for Acromegaly
Data from a Phase 3 trial presented this week at ENDO2021 showed that octreotide capsules improved clinical symptoms and other patient-reported outcomes compared to long-acting injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly. The data went on to show that 90% of patients receiving octreotide capsules elected to enroll in the open-label extension (OLE)...
Pharmaceutical Companies Team Up to Develop Acromegaly Treatment
Two pharmaceutical companies will collaborate to optimize and evaluate growth hormone receptor antagonists to select a candidate for clinical development as a potential treatment for acromegaly Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, and PeptiDream Inc., a public Kanagawa-based biopharmaceutical company, today announced a research collaboration...
Digenic Variants in Fibroblast Growth Factor 21 Signaling Linked to Severe Insulin Resistance
Variants in genes that mediate fibroblast growth factor 21 – a hormone secreted by the liver that acts to regulate the body’s response to starvation – have for the first time been linked to severe insulin resistance, according to a paper recently published in the Journal of the Endocrine Society. Researchers led by Stephen Stone,...
Girls with anorexia nervosa can have stunted growth and may not reach their full height potential, according to a new study published in The Journal of Clinical Endocrinology & Metabolism. Anorexia nervosa is a condition in which a person loses an unhealthy amount of weight on purpose by dieting, sometimes along with excessive exercise, binge eating, and/or purging behaviors. People with anorexia nervosa have an intense fear of...
The U.S. Food and Drug Administration (FDA) last month approved leuprolide acetate for injectable suspension for the treatment of pediatric patients two years of age and older with central precocious puberty (CPP). Tolmar Pharmaceuticals is marketing the drug as Fensolvi. Leuprolide acetate is the most widely used treatment for CPP. Fensolvi utilizes a proprietary polymeric gel...
Review Examines Genome-Wide Association Studies’ Effects on Understanding of Human Growth
A review recently published in The Journal of Clinical Endocrinology & Metabolism looks at how genome-wide association studies (GWASs) have impacted the medical community’s understanding of the underlying biology of human growth. The paper, by Michael H. Guo, of the Broad Institute of MIT and Harvard in Cambridge, Mass., et al., summarizes key findings of...
A French study published in the Journal of the Endocrine Society reveals myriad complications that many acromegaly patients face after they’ve been successfully treated. Lead researcher Frederic Castinetti, MD, PhD, discusses his research and why follow-up may still be required once a patient is “cured.” Last December, a paper appeared in the Journal of the Endocrine Society...
